Abstract 3773
Background
It is internationally recognised that centralisation of specialist cancer services results in improved oncologic outcomes, particularly for rare cancers. Ireland’s oncology services were formally centralised into 8 high volume cancer centres in 2007. We sought to identify changes in the utilisation of cancer treatment modalities and outcomes for patients with hepatobiliary cancers in Ireland pre and post centralisation.
Methods
Following local ethics board approval, anonymised patient data was provided by the National Cancer Registry of Ireland (NCRI) regarding all cases of hepatocellular cancer (HCC), cholangiocarcinoma and gallbladder cancers (ICD10: C22, C23 and C24) diagnosed in Ireland between 2000 – 2016. Data analysis was completed in collaboration with the NCRI.
Results
Data from 5733 patients with cholangiocarcinoma, gallbladder cancer and HCC over 16 years were analysed (Table). Similar rates of resection of all cancers were identified (21% pre 2008 and 24% from 2008 -2016). Overall 5-year survival for all cancers evaluated was significantly higher (non-overlapping CI) from 2008 -2016 - 16.1% (95% CI 14.4-17.8%) compared to pre 2008 - 12.6% (95% CI 11.0-14.4%). Despite similar rates of resection, 5-year survival rates for all resected cancers was significantly improved from 2008 - 2016 - 46.0% (95% CI 41.3-50.6%) vs 35.7% (95% CI 30.7-40.6%) prior to this. The most significant changes in use of treatment modality over the time course studied was the number of patients who received chemotherapy only (9% pre 2008 and 19% 2008 -2016, p < 0.01) and the significant increase in the number of patients who underwent adjuvant treatment (21% pre 2008 versus 42% from 2008 - 2016, p < 0.01).Table:
740P
Cancer Subtypes | 2000-2007 | 2008-2016 |
Cholangiocarcinoma | 38% (782) | 41% (1519) |
Hepatocellular Carcinoma | 17% (346) | 21% (780) |
Gallbladder | 19% (379) | 13% (497) |
Unspecified Subtype | 26% (537) | 24% (893) |
Total | 2044 | 3689 |
Conclusions
The establishment of national cancer centres in Ireland in 2007 was associated with improvement in 5-year survival for patients with hepatobiliary malignancies and with increased utilisation of systemic therapy in the advanced and adjuvant settings.
Clinical trial identification
Editorial acknowledgement
We would like to thank all the team at the National Cancer Registry of Ireland for their hard work collecting the data.
Legal entity responsible for the study
St. James’ Hospital, Dublin.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3330 - Tumour-infiltrating lymphocytes and BRCA-like status in stage III breast cancer patients treated with intensified carboplatin-based chemotherapy
Presenter: Leonora De Boo
Session: Poster Display session 2
Resources:
Abstract
3971 - Unravelling the biological characteristics of MammaPrint extreme risk subgroups
Presenter: Rajith Bhaskaran
Session: Poster Display session 2
Resources:
Abstract
5871 - Residual Cancer burden as a prognostic factor in a large series of Neoadjuvant chemotherapy. Subgroup analysis per molecular surrogated subtypes
Presenter: Catalina Falo
Session: Poster Display session 2
Resources:
Abstract
5014 - Clinical validation of CanAssist Breast in a Spanish cohort
Presenter: Manjiri Bakre
Session: Poster Display session 2
Resources:
Abstract
2787 - Meta-analysis on association of pathological complete response with long-term survival outcomes in triple-negative breast cancer
Presenter: Peter A. Fasching
Session: Poster Display session 2
Resources:
Abstract
4301 - Immune infiltrate composition across intrinsic subtypes in hormone receptor (HR)+/HER2- early breast cancer (BC) enrolled in the prospective LETLOB trial
Presenter: Gaia Griguolo
Session: Poster Display session 2
Resources:
Abstract
3205 - Frequency of germline mutations in women's cancer susceptibility genes in a large cohort of Chinese breast cancer patients
Presenter: Ning Liao
Session: Poster Display session 2
Resources:
Abstract
4091 - Triple blinded Prospective Study assessing the Impact of Genomics & Artificial Intelligence Watson For Oncology (WFO) on MDT’s Decision of Adjuvant Systemic Therapy for Hormone Receptor Positive Early Breast Carcinoma-
Presenter: Somashekhar Sampige Prasannakumar
Session: Poster Display session 2
Resources:
Abstract
4359 - Prognostic significance of Progesterone Receptor levels in luminal-like Her2- early Breast Cancer patients. A retrospective single Cancer Center analysis.
Presenter: Anna Diana
Session: Poster Display session 2
Resources:
Abstract
1369 - PAM50 HER2-enriched subtype and pathological complete response in HER2-positive early breast cancer: a meta-analysis
Presenter: Francesco Schettini
Session: Poster Display session 2
Resources:
Abstract